Haemonetics Corp. (HAE) Tops Q4 EPS by 2c, Announces Buyback Plan and Posts FY12 Guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $102.92 --0%
Revenue Growth %: +5.5%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
CAN, UNFI, SUNB, More
Revenue Growth %: +5.5%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q4 adjusted EPS of $0.85, $0.02 better than the analyst estimate of $0.83. Revenue for the quarter came in at $170 million versus the consensus estimate of $180.31 million.
Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.
he Company announced that its Board of Directors has approved a $50 million share repurchase.
Haemonetics Corp. sees FY2012 EPS of $3.50-$3.62, versus the consensus of $3.56. Haemonetics announced its fiscal 2012 annual guidance for organic revenue growth of 4-6%.
he Company announced that its Board of Directors has approved a $50 million share repurchase.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Stock BuybacksRelated Entities
Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
